Champions Oncology Inc (CSBR)

[fred the cpa]

Hi again Beaner:

I believe that every new potential drug product will have to pass through CSBR to determine whether the drug passes the test of our tumorgraft technology. If it does, then it will be passed on to the new Company. I should point out that there were several drugs that went through the tumorgraft platform that did not pass this test. However, CSBR got paid for the testing procedures on its tumorgraft platform. That is why, I believe, that this may be a net positive for CSBR. When CSBR was going to set up a library of potential cancer curing drugs it had to pay for the rights up front and then if the drug did not draw muster, it lost money on it. I repeat, I believe that this could be a positive for CSBR by increasing substantially its tumorgraft testing procedures on thes drugs and thus increasing CSBR's revenues. It also gives CSBR the opportunity through increased successful usage of its platform that it should gain interest of other biotechnology and pharmacy companies in using that platform. I would not make a decision as to whether or not this is a good or bad thing for CSBR until I had additional information.